La mia nuova descrizione qui!
Price of a print issue €25.00
Peritoneal carcinomatosis represents the advanced, final stage of peritoneal malignancy, although it is often not accompanied
by systemic neoplasia. The development of the pharmaceutical industry in combination with advanced surgery
techniques has helped to improve the outcome of these patients, considered for a long time without radical resources.
Tumoral cytoreduction followed by hypertermic intraperitoneal chemotherapy (HIPEC) is the treatment of choice for these
patients, of course, this beeing done in a multimodal treatment, carefully chosen, following a multidisciplinary consensus.
In this article we reviewed the main aspects of HIPEC procedure, describing the main chemotherapeutic agents used,
highlighting the role that they play in this oncological treatment. Finally, we have pinpointed the main research lines
in this field, which although have a well-established role in recent guidelines, have a great potential for development,
with a maximum impact on the prognosis of patients with peritoneal metastases.
